THIO and Cadonilimab in Resectable Hepatocellular Carcinoma

In this study, ateganosine (also know as THIO, 6-thio-dG, 6-thio-2'-deoxyguanosine) and cadonilimab are given via intravenous infusion. The participant will be randomly assigned to receive cadonilimab alone, ateganosine alone, or ateganosine and cadonilimab.

For this study, a cycle is defined as 21 calendar days during which drugs are administered.

If the participant is randomized to the cadonilimab alone arm, infusions will be given on the first day of every 21-day cycle. The participant will receive 2 doses of cadonilimab and then be evaluated for surgery.

If the participant is randomized to be treated with ateganosine alone, infusions of ateganosine will be given on days 1 to 3 of every 21-day cycle for 3 cycles and then the participant will be evaluated for surgery.

If the participant is randomized to be treated with ateganosine and cadonilimab, infusions of ateganosine will be given on days 1 to 3 of every 21-day cycle for 3 cycles. Infusions of cadonilimab will be given on day 5 of every 21-day cycle for 2 cycles. After receiving 3 cycles of ateganosine and 2 cycles of cadonilimab, the participant will be evaluated for surgery.